| Biomarker ID | 1252 |
| PMID | 24266816 |
| Year | 2013 |
| Biomarker | Insulin Like Growth Factor Binding Protein 3 (IGFBP3) |
| Biomarker Basis | Concentration Based (ng/mL) |
| Biomolecule | Protein |
| Source | Urine |
| Subjects | Humans |
| Regulation | Upregulated in PCa: [Controls: 0.648; Localised PCa: 0.8862] |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways include: Hypoxia and p53 in the cardiovascular system, Insulin-like growth factor (IGF) activity regulation by insulin-like growth factor binding proteins (IGFBPs), TAp63 pathway, Delta Np63 pathway, Ghrelin-mediated regulation of food intake and energy homeostasis |
| Experiment | Prostate Cancer Vs No Prostate Cancer |
| Type of Biomarker | Diagnostic |
| Cohort | Healthy men (n = 19) and men with localized (n = 65) and metastatic (n = 36) Prostate Cancer were chosen as the cohort |
| Senstivity | 98% |
| Specificity | 58% |
| AUC | 0.73 (95% CI: 0.57–0.89) |
| Accuracy | NA |
| Level Of Significance | p = 0.003 |
| Method Used | ELISA |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |